Clinerion partners with the Dresden International University for a World’s first

The Master’s Program in Clinical Research (MPCR) at Dresden International University (DIU) educates clinicians, scientists and related professionals from around the world in traditional and modern forms of clinical research in a collaborative, blended approach. With the advent of Real World Evidence (RWE) as new element in the development of innovative drugs, the University is now offering lectures in the generation of RWE from Real World Data (RWD), for the first time in such a course in the world.

The Real World Data for the course will be sourced from a subset of the de-identified electronic health records of patients in Clinerion’s hospital network. DIU Master’s students will gain access to Patient Network Explorer, Clinerion’s platform for secure, cloud-based query of remote, de-identified hospital patient data.

The collaboration will begin in August, 2019, and involve students of the 2019/2020 intake. DIU Master’s students typically have a background in fields such as oncology, neurology, cardiology and nephrology, among others. The Master’s students will already have been trained in clinical trial concepts, including study phases, trial design, biostatistics and data analysis, and scientific presentation, and will commence their Master’s research work, using Clinerion RWD, in the Fall Semester of 2020.

Students will learn how to identify student cohorts based on international terminologies, how to test feasibility and improve study protocols with real-time feedback. With an optimized set of inclusion and exclusion criteria, students will be able to access and analyze their respective patient cohort data for their Master’s thesis. Results will be presented at international meetings and published in indexed, peer-reviewed scientific journals.

“We elected to partner with Clinerion because they are at the cutting edge of the use of RWD for clinical research,” says Course Director, Dr. Ben Illigens. “Clinerion data is secure, transparent, scalable and international and therefore a perfect fit for our program and for our students’ needs. In the same way that traditional drug development can be accelerated by the availability of RWE obtained from RWD, the success of this Master’s program will be accelerated by the possibility to access Clinerion RWD. We are looking forward to presenting the results of this novel collaboration.”

(Press release)